Literature DB >> 30415577

The serum albumin threshold for increased perioperative complications after total hip arthroplasty is 3.0 g/dL.

Charles L Nelson1, Atul F Kamath1, Nabil M Elkassabany2, Zhenggang Guo3, Jiabin Liu4.   

Abstract

INTRODUCTION: : Low serum albumin is associated with higher perioperative complications following total hip arthroplasty (THA). The distinct threshold for a significant rise in perioperative complications has not been defined for THA. The purpose of this study was to define the threshold at which perioperative complications rise after THA.
METHODS: : We analysed the American College of Surgeons NSQIP database from 2006 to 2013. Our study cohort included unilateral primary THA with reported preoperative albumin levels. Patients were stratified by albumin level. We analysed mortality and 6 composite complication variables (any complication, any complication without transfusion, wound infection, systemic infection, cardiac/pulmonary complications, and any major complication). All data analysis was executed in STATA statistical software. Multivariable logistic regression analysis was used to adjust for odds ratios.
RESULTS: : The final cohort included 24,586 patients who were stratified based upon serum albumin levels. Odds ratios after multivariable regression adjustment for age, gender, race, body mass index, ASA classification, and Charlson Comorbidity Index indicated a trend to elevated odds of complication for all composite complications (3 of which were statistically significant) when serum albumin level was <3.0 g/dL.
CONCLUSION: : Low serum albumin is associated with increased perioperative complications following THA. The threshold associated with an increase in major perioperative complications appears to be an albumin level of <3.0 g/dL. With attempts to correct modifiable risk factors prior to surgery, the threshold value at which perioperative complications increase is important to define.

Entities:  

Keywords:  Malnutrition; perioperative complications; serum albumin; threshold; total hip arthroplasty

Mesh:

Substances:

Year:  2018        PMID: 30415577     DOI: 10.1177/1120700018808704

Source DB:  PubMed          Journal:  Hip Int        ISSN: 1120-7000            Impact factor:   2.135


  5 in total

1.  "Recommendations for periprosthetic joint infections (PJI) prevention: the European Knee Associates (EKA)-International Committee American Association of Hip and Knee Surgeons (AAHKS)-Arthroplasty Society in Asia (ASIA) survey of members".

Authors:  Pier Francesco Indelli; F Iannotti; A Ferretti; R Valtanen; P Prati; D Pérez Prieto; N P Kort; B Violante; N R Tandogan; A Schiavone Panni; G Pipino; M T Hirschmann
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-09-13       Impact factor: 4.342

2.  Is There Synergistic Effect Between Obesity and Hypoalbuminemia on Postoperative Outcomes Among Primary Total Shoulder Arthroplasty Recipients?

Authors:  Catherine D Buzney; Haoyan Zhong; Lawrence V Gulotta; Stavros G Memtsoudis; Jiabin Liu
Journal:  HSS J       Date:  2022-03-16

3.  The Use of Older Versus Newer Data in the National Surgical Quality Improvement Program Database Influences the Results of Total Hip Arthroplasty Outcomes Studies.

Authors:  Blake N Shultz; Anoop R Galivanche; Taylor D Ottesen; Patawut Bovonratwet; Jonathan N Grauer
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2019-10-02

4.  Preoperative Albumin, Transferrin, and Total Lymphocyte Count as Risk Markers for Postoperative Complications After Total Joint Arthroplasty: A Systematic Review.

Authors:  Chukwuemeka Mbagwu; Matthew Sloan; Alexander L Neuwirth; Ryan S Charette; Keith D Baldwin; Atul F Kamath; Bonnie Simpson Mason; Charles L Nelson
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2020-09

5.  Survival bias may explain the appearance of the obesity paradox in hip fracture patients.

Authors:  R M Amin; M Raad; S S Rao; F Musharbash; M J Best; D F Amanatullah
Journal:  Osteoporos Int       Date:  2021-07-10       Impact factor: 4.507

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.